CD19 and cancer: Cancer immunotherapy using T cells engineered ex vivo with a chimeric antigen receptor (CAR) against CD19 is currently facing major breakthroughs in the treatment of B‐cell malignancies (Davila et al, 2014; Maude et al, 2014; Kochenderfer et al, 2015; Lee et al, 2015).